<DOC>
	<DOC>NCT01716130</DOC>
	<brief_summary>To assess the acceptance of the Fluzone Intradermal (ID)vaccine in adults and vaccine administrators in the United States. Patients completed 2 surveys, one immediately post-vaccination and one seven days later, that documented demographics and assessed their injection pain, injection anxiety, speed of injection, overall satisfaction, and preference for next year's vaccine. Vaccine administrators completed one survey assessing ease of vaccine preparation and administration, time required to administer, and safety/risk of needle stick injury for patient and administrator.</brief_summary>
	<brief_title>Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators</brief_title>
	<detailed_description>Patients were divided into two groups: 1) those that reported receiving the intramuscular (IM) influenza vaccine in the past 3 years; and 2) those that reported not receiving the IM influenza vaccine in the past 3 years. The survey responses were compared between the two groups. In addition, the subjects that reported receiving the IM vaccine in the past 3 years were asked to compare their experience with the IM vaccine versus the ID vaccine.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 18 64 years of age Desire to receive the Fluzone Intradermal vaccine to protect against influenza. Less than 18 years of age, or 65 years of age and older. Desire to receive the Fluzone Intramuscular vaccine to protect against influenza. problems of the immune system, current illness, severe allergy to eggs, severe (life threatening) allergies, history of having GuillainBarre Syndrome (a severe paralytic illness) or having received a flu vaccine in the past three months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Fluzone Intradermal vaccine</keyword>
</DOC>